They're just different review processes within Health Canada. You can have a novel product and you can bring that into the Canadian marketplace. That's one pathway, or you can use the UFD as another pathway.
To address some of the concerns that were raised with respect to Mr. Cannings' point, Madam Chair, for the end-use product, the specifications between Canada and the U.S. are exactly the same. While I hear my colleague's concerns about this, we see this as being beneficial.
If you cast your mind back to the time during COVID when we didn't have any disinfectants and many of the members around this table were part of the special parliamentary committee on COVID, these shortages were in real time, and we were addressing them. We brought in 298 of those products through this interim provision, and I think it speaks to the leadership of this government to be able to address a concern in the pandemic and to also be able to reduce red tape and bring in the new regulation by embodying not only a UFD but also other pathways to the Canadian marketplace.